-- インペリアル・オイル（IMO）は金曜日、第1四半期の純利益が希薄化後1株当たり1.94カナダドル（1.43米ドル）だったと発表した。前年同期は2.52カナダドルだった。 ファクトセットが調査したアナリストは2.30カナダドルを予想していた。 3月31日締めの第1四半期の売上高は124億5000万カナダドルで、前年同期の125億2000万カナダドルから減少した。 ファクトセットが調査したアナリストは119億8000万カナダドルを予想していた。
Related Articles
Research
Research Alert: Dino: Q1 Refining Margin Strength
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DINO delivered exceptional Q1 results with adjusted EPS of $0.69 vs. a consensus loss of $0.27, beating by $0.74, while adjusted EBITDA more than doubled to $426M from $201M. The refining segment led the recovery with $514M operating income vs. a$30M loss in the prior year, though regional performance diverged with West margins expanding to $14.61/barrel while Mid-Continent compressed to $3.58/barrel. We believe the strong performance reflects improving refining fundamentals and regulatory tailwinds in renewables. The renewables segment returned to profitability with $182M operating income, benefiting from higher volumes, improved margins, and $49M in prior-year Producer Tax Credit benefits. Cash generation remained robust at $457M from operations, more than covering $167M in shareholder returns, while the balance sheet strengthened with cash rising to $1.15B. We expect continued benefit from favorable renewable diesel demand dynamics and small refinery RINs waivers.
$DINO
Research
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Iex
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.
$IEX
Australia
Oppenheimer Adjusts Price Target on Twilio to $200 From $170, Maintains Outperform Rating
Twilio (TWLO) has an average rating of overweight and mean price target of $185.40, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $172.10, Change: $+24.04, Percent Change: +16.24%
$TWLO